Literature DB >> 22608364

Genotype impact on long-term virological outcome of chronic hepatitis B virus infection.

Sebastian Malmström1, Anders Eilard, Simon B Larsson, Charles Hannoun, Gunnar Norkrans, Magnus Lindh.   

Abstract

BACKGROUND: The importance of hepatitis B virus (HBV) genotype on the clinical course of chronic HBV infection is not yet clarified.
OBJECTIVES: To investigate genotype impact on long-term virological outcome of chronic HBV infection. STUDY
DESIGN: HBsAg, HBeAg, ALT and HBV DNA levels were determined after a median of 9.2 years of follow-up of 124 adults with chronic HBV infection, of whom 33 were HBeAg-positive at inclusion.
RESULTS: HBV DNA levels decreased significantly in patients carrying genotype A (n=28), B (n=21) or D (n=63), but not in those with genotype C infection (n=12). Loss of HBeAg was seen in 44% (4/9) of patients with genotype C, as compared with 92% (22/24) with non-C genotypes. Loss of HBsAg was seen in 36% (10/28) patients with genotype A, 5% (1/21) with B, 0% (0/12) with C, and 11% (7/63) with genotype D.
CONCLUSIONS: HBV DNA levels decreased over time in patients infected with genotypes A, B or D. However, highly active genotype C or D infection often remained highly active, implying a risk for progressive liver damage.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22608364     DOI: 10.1016/j.jcv.2012.04.015

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  7 in total

1.  Loss of HBsAg and antiviral treatment: from basics to clinical significance.

Authors:  Yuecheng Yu; Jinlin Hou; Masao Omata; Yue Wang; Lanjuan Li
Journal:  Hepatol Int       Date:  2014-01-03       Impact factor: 6.047

Review 2.  Hepatitis B virus genotypes: global distribution and clinical importance.

Authors:  Mustafa Sunbul
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

3.  Characteristics of CpG Islands and their quasispecies of full-length hepatitis B virus genomes from patients at different phases of infection.

Authors:  Yuan Xue; Ming-Jie Wang; Su-Yuan Huang; Zhi-Tao Yang; De-Min Yu; Yue Han; Ming-Yu Zhu; Dao Huang; Dong-Hua Zhang; Qi-Ming Gong; Xin-Xin Zhang
Journal:  Springerplus       Date:  2016-09-21

Review 4.  Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins.

Authors:  Sanae Hayashi; Katsuya Nagaoka; Yasuhito Tanaka
Journal:  Int J Mol Sci       Date:  2021-10-13       Impact factor: 5.923

5.  How can we make decision for patients with chronic hepatitis B according to hepatitis B virus (HBV) DNA level?

Authors:  Maryam Keshvari; Seyed Moayed Alavian; Heidar Sharafi
Journal:  Hepat Mon       Date:  2014-02-05       Impact factor: 0.660

6.  A Novel Hydrodynamic Injection Mouse Model of HBV Genotype C for the Study of HBV Biology and the Anti-Viral Activity of Lamivudine.

Authors:  Xiumei Li; Guangze Liu; Meijuan Chen; Yang Yang; Yong Xie; Xiangping Kong
Journal:  Hepat Mon       Date:  2016-02-27       Impact factor: 0.660

7.  Characteristics of an outpatient chronic hepatitis B virus infection cohort.

Authors:  Danyenne Rejane de Assis; Simone de Barros Tenore; João Renato Rebello Pinho; David Salomão Lewi; Paulo Roberto Abrão Ferreira
Journal:  Einstein (Sao Paulo)       Date:  2015 Apr-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.